GlassScriptPhysician profile
Jack Parrino
NPI 1457351181
$13,115.35
in general payments reported to CMS, 2019-2025
23 companies · $1,291 in 2025
The $1,291 reported for 2025 was more than what 90% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,821 · 2020: $1,566 · 2021: $2,693 · 2022: $2,030 · 2023: $1,699 · 2024: $1,015 · 2025: $1,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,005.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $4,488.45 | 2019-2025 | Tezspire, Airsupra, Fasenra |
| Genzyme Corporation | $2,192.98 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,689.49 | 2019-2025 | Nucala, Arexvy, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $1,454.82 | 2019-2024 | Dupixent |
| Genentech USA, INC. | $556.38 | 2019-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $528.09 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $335.80 | 2019-2022 | |
| Pharming Healthcare, INC. | $321.62 | 2021-2025 | Ruconest |
| Alk-Abello, INC | $249.75 | 2019-2022 | |
| Amgen INC. | $239.13 | 2022-2025 | Tezspire |
| Teva Pharmaceuticals USA, INC. | $190.37 | 2019-2022 | |
| Pfizer INC. | $144.56 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $134.80 | 2021 | |
| Verona Pharma, INC. | $124.95 | 2025 | Ohtuvayre |
| Lilly USA, LLC | $112.20 | 2025 | Ebglyss |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $100.58 | 2019 | |
| Covis Pharma Gmbh | $78.79 | 2019-2021 | |
| Emergent Biosolutions INC. | $56.96 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.24 | 2020 | |
| Aimmune Therapeutics, INC. | $25.09 | 2021 | |
| Horizon Therapeutics Plc | $22.54 | 2021 | |
| Optinose US, INC. | $18.92 | 2019 | |
| Kaleo, INC. | $18.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Parrino listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.